Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic CD70-targeting CAR-T cells
- Development stage
- Phase 1
- Lead developer
- CRISPR Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intrathecal
01
Overview
Allogeneic CD70-targeting CAR-T cells is an investigational cell therapy being developed for the treatment of relapsed or refractory CD70-positive brain gliomas. This therapy utilizes T cells derived from healthy adult donors (allogeneic) which are genetically engineered to express a chimeric antigen receptor (CAR) specific for the CD70 antigen, a member of the tumor necrosis factor superfamily frequently overexpressed in various malignancies, including high-grade gliomas. By targeting CD70, the CAR-T cells are designed to selectively identify and eliminate glioma cells. In clinical study, the cells are administered intrathecally to facilitate direct access to the central nervous system and overcome the limitations of the blood-brain barrier.
- Other names
- Allogeneic CD70 CAR-T
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on Allogeneic CD70-targeting CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic CD70-targeting CAR-T cells.